For instance, studies have shown that inhibition of IL-8/CXCR1/2 can reduce the recruitment of immune cells and decrease the levels of pro-inflammatory cytokines, thereby potentially mitigating the inflammatory environment within the TME and reducing tumour progression and treatment resistance [34,59,85]. This evidence concerns the gene CXCR1 and neoplasm.